Stock AnalizCharles River Laboratories International (CRL) earnings for the quarter ended September 2026: EPS beats estimates
Charles River Laboratories International reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $3.09 against the analysts’ average forecast of $2.98, a beat of 3.5%.
Revenue for the quarter was $983 million, down 2.2% from $1.00 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 11.0% on the first trading day after the report.
The last four quarters
Charles River Laboratories International has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $3.09 | $2.98 | +3.5% | −2% | −11.0% |
| Jun 2026 | $3.02 | $2.74 | +10.3% | −3% | +13.4% |
| Mar 2026 | $2.06 | $1.95 | +5.4% | +1% | −2.3% |
| Dec 2025 | $2.39 | $2.35 | +1.9% | −1% | +3.6% |
What comes next
Analysts expect EPS of $3.32 for the next quarter on average and $11.47 for the fiscal year ending December 31, 2026.
The average analyst price target is $350.57, 4% above the current price of $337.97.
Valuation and score
Charles River Laboratories International scores 1.2 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 367.4, and its intrinsic value under moderate assumptions is about 76% below the current market value. Full Charles River Laboratories International analysis with 10 years of financials
Frequently asked questions
What was Charles River Laboratories International’s EPS for the quarter ended September 2026?
$3.09 adjusted per share, against an analyst consensus of $2.98.
How much revenue did Charles River Laboratories International report?
$983 million, down 2.2% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.